Insights on AI, medical research, and the future of scientific discovery.
Scoping reviews and systematic reviews are not interchangeable tools. Choosing the wrong one wastes resources at best and produces misleading conclusions at worst - and the misuse of scoping reviews to avoid rigour is a real pattern.
Read more →
The NIH now requires data sharing plans for most funded research. The "Nelson memo" changed federal open access policy overnight. The direction of travel is clear - but the tension with commercial interests in pharma research is real and unresolved.
Read more →
Network meta-analysis can rank every treatment in a therapeutic area from a single analysis - even when most of them have never been tested head-to-head. The method is powerful, and the assumptions it rests on are frequently overlooked.
Read more →
Patient-reported outcomes are not just quality-of-life questionnaires appended to trials as afterthoughts. They capture dimensions of treatment benefit and harm that clinicians systematically miss - and regulators are starting to demand them.
Read more →
Tumour shrinkage is not survival. Blood pressure reduction is not stroke prevention. The use of surrogate endpoints in clinical trials has accelerated drug approval - and produced some of medicine's most expensive mistakes.
Read more →
HARKing - presenting post-hoc hypotheses as if they were a priori - is widespread, rarely acknowledged, and one of the most direct contributors to the replication crisis. It is also not discussed honestly enough in methods training.
Read more →
Drug repurposing has produced some of medicine's most useful treatments. AI is accelerating the identification of candidates - but the gap between computational signal and clinical validation remains wide.
Read more →
Most AI assistants answer questions in a vacuum. Ours answers in the context of your entire research project.
Read more →
The forest plot is the most recognisable output of a meta-analysis - and one of the most frequently misread. Here is what the visual is actually telling you, and what it conceals.
Read more →
A hypothesis without a plan is an idea. A hypothesis with phased milestones, timelines, and go/no-go criteria is a project.
Read more →
When Bayer scientists tried to replicate preclinical oncology findings, they succeeded in fewer than a quarter of attempts. This is not an anomaly - it is a structural feature of how preclinical research is conducted and reported.
Read more →
A research tool that produces output you cannot use in your existing workflow is a tool you will stop using. Export matters more than features.
Read more →Join leading pharmaceutical companies, hospitals, biotech labs, CROs, and research centers using NousLab to accelerate medical breakthroughs.
Schedule a DemoTalk to our team to learn about licensing options for your organization